Emerald Advisers Inc. PA boosted its position in Edwards Lifesciences Corporation (NYSE:EW) by 54.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,098 shares of the medical research company’s stock after buying an additional 2,868 shares during the quarter. Emerald Advisers Inc. PA’s holdings in Edwards Lifesciences Corporation were worth $885,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Edwards Lifesciences Corporation by 2.0% during the 2nd quarter. Vanguard Group Inc. now owns 20,748,569 shares of the medical research company’s stock worth $2,453,311,000 after purchasing an additional 406,901 shares during the last quarter. BlackRock Inc. increased its position in shares of Edwards Lifesciences Corporation by 0.8% during the 2nd quarter. BlackRock Inc. now owns 14,109,514 shares of the medical research company’s stock worth $1,668,309,000 after purchasing an additional 105,819 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Edwards Lifesciences Corporation by 161.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock worth $627,207,000 after purchasing an additional 3,277,726 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Edwards Lifesciences Corporation by 13.3% during the 2nd quarter. Wells Fargo & Company MN now owns 2,119,260 shares of the medical research company’s stock worth $250,581,000 after purchasing an additional 248,293 shares during the last quarter. Finally, American Century Companies Inc. increased its position in shares of Edwards Lifesciences Corporation by 1.6% during the 2nd quarter. American Century Companies Inc. now owns 2,079,309 shares of the medical research company’s stock worth $245,857,000 after purchasing an additional 32,434 shares during the last quarter. 82.32% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/emerald-advisers-inc-pa-purchases-2868-shares-of-edwards-lifesciences-corporation-ew/1682910.html.

Edwards Lifesciences Corporation (NYSE:EW) opened at $102.72 on Monday. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $21,737.60, a P/E ratio of 28.45, a price-to-earnings-growth ratio of 1.84 and a beta of 0.46.

Edwards Lifesciences Corporation (NYSE:EW) last issued its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.02). Edwards Lifesciences Corporation had a return on equity of 27.22% and a net margin of 22.47%. The firm had revenue of $821.50 million during the quarter, compared to analyst estimates of $833.85 million. During the same period in the previous year, the company earned $0.68 EPS. Edwards Lifesciences Corporation’s revenue for the quarter was up 11.1% on a year-over-year basis. equities research analysts anticipate that Edwards Lifesciences Corporation will post 3.75 earnings per share for the current year.

In other news, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $100.93, for a total value of $3,320,597.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $101.12, for a total value of $535,936.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 171,480 shares of company stock valued at $18,855,915. Insiders own 2.13% of the company’s stock.

Several research firms have weighed in on EW. Deutsche Bank AG lowered their price target on Edwards Lifesciences Corporation from $122.00 to $115.00 and set a “hold” rating on the stock in a research report on Thursday, October 26th. Morgan Stanley decreased their target price on Edwards Lifesciences Corporation from $133.00 to $120.00 and set an “overweight” rating on the stock in a report on Thursday, October 26th. Canaccord Genuity reissued a “buy” rating and set a $155.00 target price (up from $150.00) on shares of Edwards Lifesciences Corporation in a report on Sunday, July 30th. Barclays PLC reissued an “equal weight” rating and set a $120.00 target price on shares of Edwards Lifesciences Corporation in a report on Saturday, September 30th. Finally, Cowen and Company reissued an “outperform” rating and set a $135.00 target price (up from $130.00) on shares of Edwards Lifesciences Corporation in a report on Thursday, July 27th. Seven investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $125.17.

Edwards Lifesciences Corporation Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.